

WEDNESDAY 25th MARCH 2015 COMMENCING 09.30 AM
AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0315

To protect commercial confidentiality, the first 2 appraisals will be conducted in private.

5. **Appraisal 1: Limited Submission (WPAS)**
Dolutegravir/abacavir/lamivudine (Triumeq[®]) for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 2/AWMSG/0315 Appendices
6. **Appraisal 2: Full Submission (WPAS)**
Defibrotide (Defitelio[®]) for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy in adults, adolescents, children and infants over one month of age 3/AWMSG/0315 Appendices

The meeting will now open to the public (approx 10.45am)

7. **Chairman's report (verbal update)**
8. **Appraisal 3 - Full Submission**
Daclatasvir (Daklinza[®]) in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults 4/AWMSG/0315 Appendices
9. **The role of Medication safety Officers and the process for implementation of Medication Safety Alerts in Wales** 5/AWMSG/0315
10. **Prescribing Dilemmas: A Guide for Prescribers** 6/AWMSG/0315

- | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|
| 11. Appraisal 4: Limited Submission
Entecavir (Baraclude®) for the treatment of chronic hepatitis B virus infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis | 7/AWMSG/0315
Appendices |
| 12. Appraisal 5: Full Submission
Bedaquiline (Sirturo®) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents | 8/AWMSG/0315
Appendices |
| 13. Therapeutic Priorities and CEPP Summary 2015–2016 | 9/AWMSG/0315 |
| 14. NHS Wales Primary Care Prescribing Analysis for Tramadol – Data to Sept 2014 | 10/AWMSG/0315 |

Date of next meeting:
Wednesday 22nd April 2015 at the Angel Hotel, Abergavenny